Apritant 150mg Injection
Prescription Required
Marketed By
MSN Laboratories
Pack of
1 Vial(s)
Salt Composition
Fosaprepitant Dimeglumine
Storage
keep store in cold place
₹885₹2779.31
68.16% Off
Inclusive of all taxes
1
Apritant 150mg Injection
Delivering To: —
All Substitutes
Indication
Nausea and Vomiting
Description
Apritant 150mg Injection is a prescription based medication which is used to treat nausea and vomiting associated with cancer chemotherapy. It works by blocking the neurokinin -1 (NK1) receptor in the brain, thereby preventing the signals that trigger vomiting. Medication active ingredient is Fosaprepitant Dimeglumine, a prodrug that quickly turns into aprepitant in the body, helping prevent nausea and vomiting. This injection should be administered under the supervision of a healthcare professional.
Indication
Treat nausea and vomiting in cancer patients
Common Side Effects
● Fatigue
● Diarrhea
● Indigestion
● Anemia
● Skin blistering, peeling
● Low white blood cell count
● Anemia
● Anaphylactic reactions
● Urinary tract infection
● Rash, urticaria
● Itching
● Abnormal physical weakness
● Infection
● Nerve damage
Dosage And Duration
Apritant 150mg Injection is an oral administration, taken with or without food at the fixed time everyday. Do not stop taking this medication without consultation of a healthcare provider to ensure safety and effectiveness of the treatment. Doctor suggest to regular monitor the liver function test while taking this medication. In case you missed a dose then it is better to take it as soon as possible to increase the effectiveness of the medication.
Mechanism Of Action
In cancer patients, nausea and vomiting are common symptoms. It can lead to dehydration and poor nutrition. Apritant 150mg Injection helps to reduce these symptoms by blocking neurokinin receptor which lowers both the symptoms nausea and vomiting. The medication is only used to cancer patients by improving patient comfort and enhances overall treatment outcomes.
Safety Advice
Alcohol
consult your doctor
It is unknown whether Apritant 150mg Injection are safe for patients to consume alcohol under medication. It is recommended to consult the doctor before using the medication.
Driving
consult your doctor
Apritant 150mg Injection do not cause any side effects but if you experience any side effects, consult the healthcare provider and follow the recommended dosage as prescribed by the doctor.
Pregnancy
consult your doctor
Apritant 150mg Injection contains Fosaprepitant Dimeglumine as an active ingredient which is prescribed for cancer patients. Many sources advice to take precautions for pregnant women and consult the doctor before using it.
Breast Feeding
consult your doctor
Breastfeed women should consult the doctor before taking Apritant 150mg Injection as it is important to discuss it.
Kidney
caution
Kidney patients must take a prescription from doctor while taking Apritant 150mg Injection as it should not disrupt the kidney function.
Liver
caution
Apritant 150mg Injection generally safe but it should be used with cautions in patient with kidney or liver disorder.
Faqs
Apritant 150mg Injection needed consistency, as it may take several day to show the result. Do not skip or stop taking the medication without consulting a healthcare professional.
Apritant 150mg Injection may interact with certain medications or certain medical conditions. It is essential to inform the doctor about all other medication you are taking.
Apritant 150mg Injection is taken by cancer patients who are struggling with the symptoms like nausea and vomiting.
Apritant 150mg Injection caused common side effects such as nausea, diarrhea, headache, musculoskeletal and anemia and vomiting. Visit the doctor if you are facing any severe side effects as well.
Apritant 150mg Injection is neither a targeted therapy and nor a chemotherapy. It is an antiemetic medication used to prevent nausea or vomiting cased by chemotherapy.
References
• Garnock-Jones, K. P. (2016). Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy. Drugs, 76(14), 1365-1372.
• Colon-Gonzalez, F., & Kraft, W. K. (2010). Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert opinion on drug metabolism & toxicology, 6(10), 1277-1286.
• Van Belle, S. J., & Cocquyt, V. (2008). Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opinion on Pharmacotherapy, 9(18), 3261-3270.
• Candelario, N., & Lu, M. L. R. (2016). Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives. Cancer Management and Research, 77-82.
• Cao, Z., Zhang, L., Huang, M., Xia, S., Sun, Y., Yu, X., ... & Xu, F. (2025). Development and Validation of an HPLC Method for the Simultaneous Determination of Eight Related Substances in Fosaprepitant Dimeglumine API. Chromatographia, 88(3), 205-214.
Related Products
MARKETER DETAILS
MSN Laboratories
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.